Recipharm Signs 10-Year Extension for Daewoong Pharma API

Nov 10, 2015

Recipharm has signed an agreement with Daewoong, the leading Korean-based pharmaceutical company with a strong presence in respiratory therapeutics, for a 10-year extension of its existing contract for the manufacture and supply of Erdosteine API. The finished Erdosteine product is manufactured by Daewoong Pharmaceutical at its Korean facilities. Erdosteine is indicated for the treatment of acute and chronic respiratory diseases.

According to a press release, Daewoong will annually purchase minimum API quantities of Erdosteine worth a total of about €25 million from Edmond Pharma, a Recipharm Group company. In return, Daewoong has secured exclusive rights in Korea and Thailand to sell both the original product and to register and market all the new formulations, based on Erdosteine, which are currently under development at Edmond Pharma.

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments